Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 07:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018

Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on...
November 07, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO)

Dr. Woodman is appointed CMO and Senior Vice President of Research & Development, joining Onconova after multiple accomplishments at NovartisOther recent hires in Clinical and Regulatory Affairs...
November 05, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition

Oral presentation on Saturday will feature efficacy and safety data from Expanded Phase 2 trial of rigosertib in combination with AzacitidineThree Poster presentations to feature pharmacokinetics,...
November 01, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, November 13, 2018 NEWTOWN, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a...
October 29, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark

NEWTOWN, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
October 17, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib

Granted claims cover both oral and injectable formulations of RigosertibNewly issued US patent 10,098,862 extends protection for Rigosertib into 2037Equivalent coverage is being sought worldwide and,...
October 10, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco

NEWTOWN, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
September 25, 2018 09:16 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Reverse Stock Split

Reverse split intended primarily to increase the per share bid price of Onconova's common stock and satisfy the Nasdaq Capital Market continued listing requirement NEWTOWN, Pa., Sept. 25, 2018 ...
August 28, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference in New York City

NEWTOWN, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
August 21, 2018 08:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma

Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina, Chile, and Brazil in preparation for future studies of oral rigosertib NEWTOWN, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) --...